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Objectives: The aim was to estimate the cost-effectiveness of using an extensively hydro-
lyzed casein formula (eHCF) plus the probiotic Lactobacillus rhamnosus GG (eHCF + LGG; 
Nutramigen LGG) compared to an eHCF alone (Nutramigen) and an amino acid formula (AAF; 
Neocate) as first-line dietary management for cow’s milk allergy (CMA) in the US.
Methods: Using a cohort study design, the analysis was based on the case records of 136 
eHCF-fed, 59 eHCF + LGG-fed, and 217 matched AAF-fed infants extracted from the Truven 
Health MarketScan® Commercial Claims Database (a nationally representative database of the 
commercially insured population of the US). Clinical outcomes and health care resource use (with 
corresponding costs at 2012 prices), following first-line dietary management with each formula, 
were estimated over 12 months from the start of feeding. Differences in infants’ outcomes and 
resource use between groups were adjusted for any differences in baseline covariates.
Results: Infants were ,6 months of age at presentation. Fifty-six percent of eHCF + LGG-fed 
infants were estimated to have been successfully managed by 9 months compared to 38% of 
eHCF-fed infants and 35% of AAF-fed infants (P,0.05 and P=0.003 respectively). Infants in 
the AAF group used significantly more health care resources and prescribed drugs than infants 
in the other two groups. The estimated cost of managing a CMA infant over the first 12 months 
following the start of feeding was $3,577, $3,781, and $6,255 for an eHCF + LGG-fed, eHCF-
fed, and AAF-fed infant, respectively. Parents’ costs accounted for up to 10% of the total costs 
and the remainder was incurred by insurers. The analyses were robust to plausible changes in 
all variables.
Conclusion: Using real world evidence, initial dietary management with eHCF + LGG appears 
to afford a more cost-effective use of health care resources than initial dietary management with 
eHCF or AAF since it releases health care resources for alternative use within the system and 
reduces costs without impacting on the time needed to manage the allergy.
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Introduction
Cow’s milk allergy (CMA) is an abnormal immune response to milk proteins.1 Its inci-
dence in infancy in Western industrialized countries has been estimated at 2%–3%,2,3 





and it generally develops within the first few months of life. 
However, up to 90% of affected infants naturally develop 
tolerance to cow’s milk proteins by 5 years of age.3 There 
are several guidelines addressing the management of infants 
with CMA.2,4,5 These guidelines all recommend the use of 
substitutive hypoallergenic formulas,4,5 including exten-
sively hydrolyzed formulas (eHFs) and amino acid formulas 
(AAFs). The clinical properties of these formulas have been 
reviewed elsewhere.6–10
The addition of the probiotic Lactobacillus rhamnosus 
GG (LGG) to the extensively hydrolyzed casein formula 
(eHCF), Nutramigen (eHCF + LGG) has been shown to 
accelerate the development of tolerance to cow’s milk in 
infants with CMA compared with those receiving other 
hypoallergenic formulas.11,12 In the most recent study,12 it was 
reported that significantly more infants in the eHCF + LGG 
group (both those with immunoglobulin E [IgE]-mediated 
and those with non-IgE-mediated CMA) developed tolerance 
to cow’s milk by 12 months (78.9%; P,0.05) than those fed 
other formulas: eHF alone (43.6%), hydrolyzed rice formulas 
(32.6%), soy-based formulas (23.6%), and AAF (18.2%). 
Binary logistic regression revealed that the rate of infants 
developing tolerance at the end of the study was influenced 
by two factors: 1) IgE-mediated mechanism (odds ratio: 0.12; 
P,0.001) and 2) the choice of formula eHCF + LGG (odds 
ratio: 28.62; P,0.001).
We have previously reported the cost-effectiveness of start-
ing management for CMA with the eHCF, Nutramigen instead 
of the AAF, Neocate13 in the UK. This current study estimated 
the cost-effectiveness of using eHCF + LGG compared with 
eHCF alone (ie, Nutramigen) and AAF (ie, Neocate) as first-
line dietary management for CMA in the US.
Methods
Truven health Marketscan Commercial 
Claims and Encounters Database
The Truven Health MarketScan® Commercial Claims 
 Database (Truven Health Analytics Inc., Ann Arbor, MI, US) 
is a tool for investigating health care resource consumption 
in the US. The database comprises fully adjudicated and paid 
claims pertaining to integrated enrollment and data on inpa-
tients, outpatients, and drugs, as well as all plan designs (ie, 
health maintenance organizations, preferred provider organi-
zations, fee-for-service, etc). The data contained in the data-
base are broadly representative of the commercially insured 
population of the US, with beneficiaries in all 50 states, 
Washington DC, Puerto Rico, and the US Virgin Islands. 
Data fields include, but are not limited to,  descriptions of the 
different providers, pharmaceutical  prescriptions,  reimbursed 
clinical nutrition preparations, clinical variables (eg, symp-
toms, clinician visits, hospital admissions, and length of time 
being managed), and financial variables (ie, costs incurred 
by insurers and parents).
study population
The study population was derived from those states where 
eHCF + LGG, eHCF, and AAF are reimbursed. The database 
contained the records of 875 infants who had been diagnosed 
as having CMA by their pediatrician and who were managed 
between October 1, 2006, and October 30, 2012. Of these, 
265 eHCF-fed infants were matched with 265 AAF-fed 
infants and 115 eHCF + LGG–fed infants were matched 
with 115 AAF-fed infants.
The infants fed eHCF or eHCF + LGG were ,1 year of 
age when diagnosed with CMA, received a prescription for 
eHCF or eHCF + LGG as their first clinical nutrition prepa-
ration for CMA, and had at least 12 months’ follow-up data 
from the time of their first formula prescription. These infants 
were matched with AAF-fed infants according to age, sex, 
date of starting formula, having received a prescription for 
AAF as their first clinical nutrition preparation for CMA, 
and having at least 12 months’ follow-up data from the date 
of their first prescription for AAF.
129 eHCF-fed, 56 eHCF + LGG-fed, and 163 AAF-fed 
infants were excluded from the data set because they were 
premature, they had less than six prescriptions for any of the 
formulas of interest, or they had serious overlapping health 
conditions, and therefore, consumed a disproportionate 
amount of resource use that was not indicative of CMA. 
Hence, 136 eHCF-fed and 148 matched AAF-fed infants 
and 59 eHCF + LGG-fed and 69 matched AAF-fed infants 
were eligible for analysis.
The data set used for this study did not involve inter-
action or interview with any subjects, and the records do 
not include any individually identifiable data (eg, names, 
addresses, social security or medical record numbers, or 
other obvious identifiers). Consequently, this study was 
not research involving human subjects as defined under 
US law. Hence, institutional review board approval was 
not required.
study variables and statistical analyses
Information extracted from infants’ records included age 
and sex at baseline. Additionally, all information on CMA-
related health care resource use, prescribed drug medication, 
prescribed clinical nutrition preparations, and costs to parents 
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and insurers over a period of 12 months from the date of 
starting a formula was extracted.
Infants were assumed to have been successfully managed 
if they stopped using a formula and also stopped receiving 
medication for the symptoms of CMA, such as H
2
 antago-
nists, proton pump inhibitors, topical dermatologicals, and 
antihistamines.
Infants’ outcomes and resource use were quantified for 
each group. Results are presented as mean ± standard error 
or as percentages. Differences between groups were tested 
for statistical significance using a Kruskal–Wallis one-way 
analysis of variance or a chi-square test to determine which 
means or percentages were similar and which were different. 
These tests revealed that there were no differences between 
the two AAF groups across any of the studied parameters 
(P.0.820); hence they were combined to form one group 
of 217 patients.
Using analysis of covariance, differences in infants’ 
outcomes and resource use between formulas were adjusted 
for any differences in the following covariates: age, sex, 
feeding start date, and the US state in which the infants 
were managed. Regression analyses were used to investigate 
relationships between baseline variables on resource use and 
clinical outcomes. All statistical analyses were performed 
using IBM SPSS Statistics (v21.0; IBM Corporation, 
Armonk, NY).
health economic modeling
A decision model was constructed in MS Excel depicting 
the management of the cohort of infants in each group. The 
model was populated with health care resource utilization and 
clinical outcomes extracted from the data sets and spanned 
a period of 12 months from the start of feeding with eHCF 
+ LGG, eHCF, or AAF.
Model outputs
The model estimated clinical outcomes and health care 
resource use at 12 months. Using the US inflation indexes, 
costs incurred by parents and insurers were uprated to 2012 
prices in order to estimate the costs over 12 months from 
starting a formula.
Cost-effectiveness analyses
Effectiveness was defined as the probability of infants having 
been successfully managed (ie, they stopped using a formula 
and also stopped receiving medication for the symptoms of 
CMA). The cost-effectiveness of 1) eHCF + LGG compared 
to AAF, 2) eHCF compared to AAF, and 3) eHCF + LGG 
compared to eHCF was calculated as the difference between 
the expected management costs over 12 months from the 
start of feeding divided by the difference in the probability 
of infants being successfully managed by 12 months, and it 
is expressed as the cost per additional successfully managed 
infant. If one of the formulas improved the probability of 
an infant being successfully managed for less cost, it was 
considered to be the dominant (cost-effective) formula.
sensitivity analyses
To assess uncertainty, bootstrapping was undertaken to 
estimate the distribution of expected costs, outcomes, and 
cost-effectiveness ratios. This involved generating 10,000 
subsets of the data from each group on the basis of random 
sampling and replacing the data once sampled.  Additionally, 
deterministic sensitivity analyses were performed on all the 
models’ inputs to identify how the difference in cost per infant 




Among the study population, 49% of eHCF-fed, 46% 
of eHCF + LGG-fed, and 52% of AAF-fed infants were 
female. Additionally, the mean age of the eHCF group 
(1.9±0.2 months) at the time of presentation was significantly 
lower than that of the eHCF + LGG group (2.7±0.2 months; 
P,0.05) and the AAF group (3.0±0.2 months; P,0.001). 
There was no significant difference between the mean ages 
of the eHCF + LGG and AAF groups.
infant management and outcomes
There were no significant differences in the length of time 
on a formula among the three groups. Ten percent of the 
136 eHCF-fed infants changed to eHCF + LGG after a mean 
5.4±0.3 months and 9% switched to an AAF after a mean 
3.4±0.4 months, whereas 7% of the 59 eHCF + LGG-fed 
infants switched to an AAF after a mean 2.4±0.2 months. 
None of the 217 AAF-fed infants switched formulas. This 
is consistent with the results of our previous study13 in the 
UK, which showed that in clinical practice, 10% of eHCF-
fed infants switch to an AAF and no AAF infants switch to 
other formulas.
Infants in the eHCF group continued feeding with a 
formula for a mean of 9.0±0.3 months and received a mean 
8.7±0.5 prescriptions. Infants in the eHCF + LGG group con-
tinued feeding with a formula for a mean of 8.1±0.5 months 
and received a mean 7.9±0.4 prescriptions. Infants in the 





AAF group continued feeding with a formula for a mean of 
9.3±0.2 months and received a mean 10.5±0.5 prescriptions 
per infant.
After 9 months from starting a formula, 56% of infants in 
the eHCF + LGG group were estimated to have been success-
fully managed because they stopped using a formula and also 
stopped receiving medication for symptoms of CMA. This 
was significantly more than the infants who were estimated 
to be successfully managed in both the eHCF (38%; P,0.05) 
and AAF groups (35%; P=0.003). There was no significant 
difference between the percentages of infants successfully 
managed in the eHCF and AAF groups at 9 months. By 
12 months after having started a formula, 64% of infants in 
the eHCF + LGG group were estimated to have been suc-
cessfully managed. This was significantly more than those 
estimated to have been successfully managed in the AAF 
group (43%; P=0.02). However, by 12 months, there were 
no longer any significant differences between the percentages 
of infants successfully managed in the eHCF group (51%) 
and the eHCF + LGG or AAF groups (Figure 1).
health care resource use associated  
with infant management
Infants in the AAF group used significantly more health care 
resources and prescribed drugs than infants in the other two 
groups (Table 1). However, there were no significant differ-
ences in hospital admissions. One infant in each group was 
admitted into hospital for CMA-related symptoms.
In addition to CMA-related health care resource use, 
four eHCF-fed infants were admitted into hospital for a 
mean of 6 days for asthma, pneumonia, or viral meningitis, 
one eHCF + LGG-fed infant was admitted into hospital for 
2 days for asthma, and 15 AAF-fed infants were admitted 
into hospital for a mean of 3 days for asthma, bronchitis, 
pneumonia, gastrointestinal disease, infection, or viral 
meningitis during the study period. One of these infants 
was admitted for cardiac function tests. Additionally, in 
all three groups, infants received a mean of three prescrip-
tions for an  antibiotic. Infants in all three groups received 
,0.1 prescriptions for any other drug group.
Multiple regression analysis showed that an infant’s age 
at the time of starting a formula influenced the length of time 
on formula. The length of time on a formula decreased by 
1 month for every 4 months of age (P=0.001).
health care cost of infant management
The total 12-monthly cost of infant management from start-
ing a formula was $3,577±466 per infant in the eHCF + 
LGG group, $3,781±299 per infant in the eHCF group, and 
$6,255±225 per infant in the AAF group. Of this cost, ,10% 
was incurred by parents (Table 2).
Use of eHCF + LGG instead of eHCF or AAF reduced 
the following:
1. Parent costs by $69 and $349 per infant, respectively.
2. Insurer costs by $135 and $2,330 per infant, respectively.
3. Total costs by $204 and $2,679 per infant, respectively.
Cost-effectiveness analyses
Proportionally more infants in the eHCF + LGG group 
were successfully managed compared to those in the 
eHCF and AAF groups. Additionally, starting management 
with eHCF + LGG instead of eHCF or an AAF reduced 







































Time to successful management (months)
1 2 3 4 5 6 7 8 9 10 11 12
Figure 1 Time to successful management of cow’s milk allergy.
Abbreviations: ehCF, extensively hydrolyzed casein formula; ehCF + lgg, 
extensively hydrolyzed casein formula plus the probiotic Lactobacillus rhamnosus gg; 
aaF, amino acid formula.
Table 1 Mean cow’s milk allergy-related health care resource 
use per infant over the study period
eHCF  
group




number of infants 136 59 217
Mean number per infant
  Outpatient visits  
to see a physician
2.16±1.39* 3.24±0.56* 8.88±1.05*
  Diagnostic and  
laboratory tests
4.20±0.76** 4.68±1.18** 8.22±0.57**
  hospital admissions 0.01±0.01 0.02±0.02 0.01±0.01
Percentage of infants who received
  gastrointestinal drugs 41%*** 41%*** 59%***
  Topical preparations 23% 9% 15%
  antihistamines 0% 0% 1%
  adrenalin 5% 2% 9%
Notes: Values are shown as mean ± standard error. *The AAF group is significantly 
different from the other two; P=0.001. **The AAF group is significantly different 
from the other two; P=0.001. ***The AAF group is significantly different from the 
other two; P=0.002.
Abbreviations: ehCF, extensively hydrolyzed casein formula; ehCF + lgg, 
extensively hydrolyzed casein formula plus the probiotic Lactobacillus rhamnosus gg; 
aaF, amino acid formula.
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Table 2 Cost of infant management (in Us $ at 2012 prices)
 eHCF group eHCF + LGG group AAF group
Parent  
cost per  
infant
Insurer  
cost per  
infant
Total  
cost per  
infant
Parent  
cost per  
infant
Insurer  
cost per  
infant
Total  
cost per  
infant
Parent  
cost per  
infant
Insurer  
cost per  
infant
Total  
cost per  
infant
Outpatient visits  
to see a physician
$72.08 $465.92 $538.00 $51.69 $420.66 $472.35 $178.30 $1,196.21 $1,374.51
ehCF $203.14 $2,387.06 $2,590.20
ehCF + lgg $168.15 $2,344.55 $2,512.70
aaF $6.14 $227.97 $234.11 $1.69 $193.91 $195.60 $335.42 $3,853.12 $4,188.54
Other prescriptions $66.27 $304.43 $370.70 $53.28 $285.54 $338.82 $105.28 $500.72 $606.00
hospitalization $0.00 $48.29 $48.29 $3.67 $53.81 $57.48 $8.35 $78.22 $86.57
Total $347.63 $3,433.67 $3,781.30 $278.48 $3,298.47 $3,576.95 $627.35 $5,628.27 $6,255.62
Abbreviations: ehCF, extensively hydrolyzed casein formula; ehCF + lgg, extensively hydrolyzed casein formula plus the probiotic Lactobacillus rhamnosus gg; 


































50 100 150 200
Time to being successfully managed (days)
250 300 350 400
AAF
Figure 2 Distribution of insurers’ costs and time to being successfully managed, generated by bootstrapping.
Abbreviations: ehCF, extensively hydrolyzed casein formula; ehCF + lgg, extensively hydrolyzed casein formula plus the probiotic Lactobacillus rhamnosus gg; 
aaF, amino acid formula.
eHCF + LGG instead of an eHCF or an AAF was found 
to be the dominant strategy because it improved outcome 
for least cost. Additionally, starting management with an 
eHCF instead of an AAF also improved outcome for least 
cost. Hence, initial management of CMA infants with eHCF 
instead of an AAF was found to be a dominant strategy.
sensitivity analyses
Bootstrapping demonstrated the distribution in the insurers’ 
cost per infant and time to successful management. The analy-
sis showed that the eHCF + LGG, eHCF, and AAF groups are 
three distinct cohorts with minimal overlap (Figure 2).
Deterministic sensitivity analyses (Table 3) showed that 
plausible changes in the model’s inputs did not change the 
finding that the cost of managing infants with eHCF + LGG 
was less than that of managing infants with eHCF or AAF.
Discussion
A review of published literature suggests this to be the first 
study to assess the cost-effectiveness of using eHCF + LGG 
compared with an eHCF or AAF in the management of CMA 
in the US. This study made use of the complete sample of 
infants in the Truven Health MarketScan  Commercial Claims 
Database who had a diagnosis of CMA and who received either 
first-line eHCF + LGG or eHCF and who were compared 
with matched infants who received first-line AAF, and who 
had a clinical history for at least one year. The advantage of 
using real world evidence from the MarketScan Commercial 





Claims Database is that the infant pathways and associated 
resource use are based on actual clinical practice rather than 
trial protocol-driven resource use. However, this naturalistic 
approach does have its limitations. Infants were not random-
ized to the formula they received and resource use, whilst 
collected prospectively, were analyzed retrospectively. There 
was no evidence to suggest that infants who were initially 
managed with an AAF had more severe symptoms. However, 
that possibility cannot be excluded. Undoubtedly, there would 
have been differences between the groups, resulting in the 
hospital physician’s decision to initially manage an infant with 
one of the formulas and the parents’ willingness to agree to 
feed their infant the prescribed formula. Every attempt was 
made to account for these differences and to overcome the 
nonrandomized study design. Differences in clinical outcome 
and resource use between formulas were adjusted for any 
heterogeneity in age, sex, feeding start date, and US state. 
Moreover, the sample sizes should have been sufficiently 
large enough to allow for relevant baseline differences to be 
apparent. Nevertheless, there will have been some differences 
that have not been accounted for. It is challenging to power 
health economic studies in which the metric is use of different 
resources or a range of clinical outcomes that are unknown at 
the outset. However, power calculations showed that the sample 
size was sufficiently large to detect any significant differences 
in resource use with 95% power and a type I (alpha) error of 
0.05 between the two groups, had they occurred.
For infants to have been included in the data set for this 
study, their clinician had to have documented a diagnosis of 
CMA in their case records. However, it is unlikely that all of 
these infants would have undergone a double-blind placebo-
controlled food challenge. Hence, it is probable that some 
infants did not have a differential diagnosis of CMA. As a 
result, infants with suspected CMA were managed by their 
clinician on the basis of presenting symptoms and symptom 
resolution. This is how many infants are diagnosed in clinical 
practice13 and therefore the diagnosis of CMA may not be 
secure in all cases. Therefore, we excluded those infants for 
whom we had some uncertainty about their diagnosis, such as 
those who did not have at least six consecutive prescriptions 
for a hypoallergenic formula. Consequently, the outcomes 
and estimates of health care resource use and corresponding 
costs in this analysis may have been derived from actual and 
perceived cases of CMA. Notwithstanding this, after adjust-
ing for baseline differences, this study estimated that over the 
first 12 months following the start of a formula, initial use of 
eHCF + LGG instead of eHCF or an AAF improved outcomes 
and reduced both parent costs and insurer costs.
By assuming that infants had been successfully managed 
if they stopped using a formula and also stopped receiving 
medication for the symptoms of CMA, the analysis found 
that more infants fed with eHCF + LGG were successfully 
managed by 12 months than those who were fed either of 
the other two formulas. This trend was concordant with the 
findings of a study among an Italian population,12 which 
assessed the time to acquiring tolerance to cow’s milk. The 
Italian study evaluated tolerance acquisition in infants with 
IgE-mediated and non-IgE-mediated allergy separately, 
and tolerance development was determined by an oral food 
challenge.12 In our study, the extent of IgE involvement is 
unknown. Nevertheless, the Italian study previously reported 
that the percentage of infants developing tolerance to cow’s 
milk was greater among those fed eHCF + LGG than among 
those fed a casein-based or whey-based eHF, which was 
in turn greater than those fed an AAF.12 This trend is also 
consistent with the findings from other studies.11
There were no other published studies assessing the 
health economic impact of alternative formulas for the 
Table 3 sensitivity analyses
Scenario eHCF-fed versus eHCF + LGG-fed infants AAF-fed versus eHCF-fed infants
Parents’ perspective Insurers’ perspective Parents’ perspective Insurers’ perspective
The difference in the number of  
outpatient visits between the groups  
ranges from 0 to 10 visits per infant
$50–$240 per infant $90–$500 per infant $170–$340 per infant $1,500–$2,600 per  
infant
The difference in the cash value of  
formulas to insurers between the groups  
ranges from $10 to $400 per infant
$130–$520 per infant $2,000–$2,400 per  
infant
The difference in the cash value of  
formulas to parents between the groups  
ranges from $10 to $100 per infant
$70–$160 per infant $250–$340 per infant
Notes: Differences in mean costs per infant between alternative formulas from parents’ and insurers’ perspectives.
Abbreviations: ehCF, extensively hydrolyzed casein formula; ehCF + lgg, extensively hydrolyzed casein formula plus the probiotic Lactobacillus rhamnosus gg; aaF, 
amino acid formula.
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management of CMA, except our previous study,13 which 
estimated the cost-effectiveness of eHCF compared to AAF 
in the UK. The observations made in our UK study reinforce 
our current findings that eHCF affords a cost-effective use of 
health care resources when compared to AAF.13 This study 
is also subject to limitations that are similar to those in our 
UK study.13 The results were censored at 12 months and 
excluded the costs and consequences of managing infants 
beyond this period. The database may have underrecorded 
the use of some health care resources, such as some home 
visits made by clinicians. The analysis only considered the 
cost of resource use for the “average infant,” and no attempt 
was made to stratify resource use and costs according to sex, 
comorbidities, suitability of infants for different formulas, 
and other disease-related factors. Nevertheless, sensitivity 
analyses demonstrated that plausible changes in resource 
use had minimal effect on the relative cost-effectiveness of 
the three formulas. Also excluded were the indirect costs 
incurred by society as a result of parents taking time off 
work. The analysis excluded changes in quality of life and 
improvements in general well-being of sufferers and their 
parents as well as parents’ preferences. Changes in infants’ 
behavior were also excluded. Consequently, this study may 
have underestimated the relative cost-effectiveness of the 
formulas.
This evaluation provides an estimate of the resource 
implications and the associated costs and outcomes attribut-
able to managing infants with CMA in the US, based on real 
world evidence. Although the study results were compelling, 
the analyses were based on entries in the MarketScan Com-
mercial Claims Database and were inevitably subject to a 
certain amount of imprecision and lack of detail. Moreover, 
the computerized information in the database is collected 
for accounting purposes and not for research. Prescriptions 
issued by clinicians are recorded in the database, but it does 
not specify whether the prescriptions were dispensed or level 
of infant compliance with the product. Consequently, this 
study’s findings should provide the basis for a randomized 
controlled trial comparing the three formulas in the manage-
ment of different phenotypes of CMA to prospectively mea-
sure a range of clinical outcomes and health-related quality 
of life, in combination with cost-effectiveness metrics.
In conclusion, within the limitations of the data set, initial 
dietary management with eHCF + LGG affords a more cost-
effective use of health care resources than initial dietary man-
agement with eHCF or AAF because it releases health care 
resources for alternative use within the system and reduces 
costs without impacting on the time needed to manage the 
allergy. However, a randomized, controlled study in children 
receiving a probiotic-containing formula is required before 
this conclusion can be confirmed.
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